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Abstract: Joint tissues like synovium, articular cartilage, meniscus and subchondral bone,
are targets for neuropeptides. Resident cells of these tissues express receptors for various
neuroendocrine-derived peptides including proopiomelanocortin (POMC)-derived peptides, i.e.,
α-melanocyte-stimulating hormone (α-MSH), adrenocorticotropin (ACTH) and β-endorphin (β-ED),
and sympathetic neuropeptides like vasoactive intestinal peptide (VIP) and neuropeptide y (NPY).
Melanocortins attained particular attention due to their immunomodulatory and anti-inflammatory
effects in several tissues and organs. In particular, α-MSH, ACTH and specific melanocortin-receptor
(MCR) agonists appear to have promising anti-inflammatory actions demonstrated in animal models
of experimentally induced arthritis and osteoarthritis (OA). Sympathetic neuropeptides have obtained
increasing attention as they have crucial trophic effects that are critical for joint tissue and bone
homeostasis. VIP and NPY are implicated in direct and indirect activation of several anabolic
signaling pathways in bone and synovial cells. Additionally, pituitary adenylate cyclase-activating
polypeptide (PACAP) proved to be chondroprotective and, thus, might be a novel target in OA. Taken
together, it appears more and more likely that the anabolic effects of these neuroendocrine peptides
or their respective receptor agonists/antagonists may be exploited for the treatment of patients with
inflammatory and degenerative joint diseases in the future.
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1. Introduction
Clinical symptoms of osteoarthritis (OA) appear in more than 10% of the world population and
affect almost everyone over the age of 65. As a consequence of the increasing longevity and obesity
within the European Community, the economic and social burden caused by OA is growing rapidly
and substantially influences the life quality of the affected individuals causing enormous costs to the
health care system for diagnosis, treatment, sick leave, rehabilitation, and early retirement [1]. A recent
survey in 15 European countries revealed that, on average, 19% of the population suffer from chronic
pain, most frequently caused by disorders of the musculoskeletal system, specifically OA, herniated
and/or deteriorating discs, traumatic injury and rheumatoid arthritis [2]. This study also documented,
that a majority of patients with pain experience sleep disturbances and a reduced ability to exercise, lift,
and walk. Moreover, chronic pain may prevent attending social activities, to work in and outside the
house, to maintain an independent life style, to have a normal sexual life, etc. The burden of OA not
only includes physical problems, it also has detrimental psychological effects. Psychological distress is
more frequently experienced by patients with OA compared to patients with other chronic diseases
such as diabetes [3].
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Current pharmacological strategies either seek to relieve pain and increase mobility (symptom
modifying drugs) or aim to affect the disease (DMOAD, disease modifying osteoarthritis drugs). Pain
is treated with non-steroidal anti-inflammatory drugs, cyclo-oxygenase (COX)-2 inhibitors, opioids,
corticosteroids, viscosupplementation and symptomatic slow-acting drugs [4]. To date, none of the
current DMOAD-based approaches was able to stop disease progression, nor regenerate damaged
cartilage in the long term [5]. The OARSI guidelines recommend glucosamine- and chondroitin
sulfates and diacerein as DMOADs, and the National Institute for Health and Clinical Excellence
will recommend glucosamine sulfate in the next update of their guidelines. Especially, glucosamine
derivatives are promising DMOADS and show a highly protective capacity in OA animal models
after intra-articular injection [6]. Exploration of improved outcome measures and identification of
subgroups of patients benefiting from different DMOADs are the most important areas of research for
the coming years [7,8].
Often this treatment is insufficient and, finally, after many years of pain, most patients have to
undergo surgical joint replacement therapy, e.g., total knee arthroplasty. Thus, there is an ultimate
need for the development of new, non-invasive or minimal-invasive treatments that could slow down
and/or stop OA progression and substitute joint replacement for end-stage OA-patients. These may
include therapeutic options with neurohormones like proopiomelanocortin (POMC)-derived peptides
and neuropeptides of the sympathetic and parasympathetic nervous system.
2. Biology of POMC-Derived Peptides and Their Receptors
2.1. POMC Gene Expression and Processing
POMC is a multifunctional precursor protein for several biologically active hormones which
include adrenocorticotropin (ACTH), the melanocyte-stimulating hormones (α-, β- and γ-MSH) and
the endogenous opioid β-endorphin (β-ED). The human POMC gene is composed of three exons and
two large introns. Exon 1 is untranslated while parts of exon 2 code for the signal sequence. Exon 3
codes for the bioactive POMC-derived peptides which are generated after proteolytic processing of
POMC [9]. Only the full length POMC transcript (1200 bp) is functional, smaller transcripts are neither
processed nor secreted. Glucocorticoids acting via glucocorticoid-responsive elements repress POMC
transcription whereas in peripheral cell types pro-inflammatory stressors including ultraviolet light
irradiation, pro-inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-α
and the tumor suppressor gene product p53 turn on POMC expression [10]. Epigenetic mechanisms
involving hypermethylation of a CpG-rich island upstream of exon 1 in the 5′ POMC promoter region
control POMC gene expression [11], however, in many peripheral tissues the POMC promoter is
permanently methylated. After translation, the ~30 kDa POMC precursor protein is further processed
by prohormone convertases (PCs) [12]. PC1 cleaves POMC into ACTH and β-lipotropic hormone
whereas PC2 further processes ACTH and β-lipotropic hormone to the various MSHs (α-MSH, γ-MSH
and β-MSH) as well as β-endorphin (β-ED). Although POMC is considered a precursor protein for
the above listed biologically active peptide hormones it should be noted that full-length POMC also
possesses weak melanotropic activity in vitro [13].
2.2. POMC-Derived Peptide Receptors
The melanocortin peptides ACTH and α-, β- and γ-MSH bind with high affinity to melanocortin
receptors (MCRs) which belong to the superfamily of G-protein coupled receptors (GPCRs) with
seven transmembrane domains [14]. Five MCR subtypes, MC1R to MC5R, have been cloned which
have a sequence homology of 39–61% to one another at the amino acid level. The MCR subtypes
bind melanocortins with different affinities. MC1R binds both, ACTH and α-MSH, with almost
equal affinity while MC2R is selective for ACTH. However, ACTH also binds to MC3R, MC4R and
MC5R, although γ-MSH is the preferred ligand for MC3R and α-MSH the preferred ligand for the
MC5R. Signal transduction is mediated via increase in cyclic adenosine monophosphate (cAMP)
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and also Ca2+ mobilization from intracellular stores [12]. For in depth description of melanocortin
receptors, their regulation of activity and signal transduction pathways see the recent review from
Montero-Melendez [15]. In the presence of pro-inflammatory co-stimuli such as IL-1 or TNF-α,
melanocortin peptides suppress signal transduction pathways linked to inflammation and immune
responses. This has been demonstrated for various MC1R-expressing cell types in which α-MSH can
significantly attenuate activation of the redox-sensitive nuclear factor-κB (NF-κB) [16].
β-ED has high affinity for both the µ-opioid receptor (MOR) and δ-opioid receptor (DOR); both
are G-protein coupled receptors. In analogy to MCRs, MORs and DORs have been detected in an
increasing number of extra-neural tissues and non-neuronal cells indicating functions of β-ED far
beyond anti-nociception [17]. The signaling events elicited by β-ED are complex and mediated via
more different intracellular pathways compared to MCR-mediated responses and are not the focus of
this review.
3. Biology of Sympathetic Neuropeptides and Their Receptors
The classical neurotransmitters of sympathetic and parasympathetic nerves are noradrenaline (NE)
and acetylcholine (ACh), respectively. Both types of nerve fibers can be accompanied by peptidergic
transmitters and some nerve fiber types predominantly express neuropeptides as their main transmitter.
Catecholaminergic sympathetic neurons often co-express neuropeptide Y (NPY) [18,19], whereas
ACh co-localizes with vasoactive intestinal peptide (VIP) [20,21]. Alongside, peptides like pituitary
adenylate cyclase-activating peptide (PACAP) and enkephalin and somatostatin have been described in
the sympathetic nervous system [22,23]. In this review, we will focus on the peptidergic co-transmitters
of peripheral sympathetic and parasympathetic nerves, especially in the musculoskeletal system.
3.1. Neuropeptide Y
NPY is a 36-amino-acid peptide first isolated and sequenced from porcine brain extracts in 1982
by Tatemoto et al. [24]. The highly homologous neuropeptide Y family of biologically active peptides
also includes peptide YY (PYY) and the pancreatic polypeptide (PP) sharing a characteristic of high
numbers of tyrosine residues in their sequence [25]. Beside its manifold functions in the central nervous
system, peripheral actions involve modulation of inflammatory or neuropathic pain [26], regulation
of the gut-brain axis [27] and the cardiovascular system [28,29] as well as angiogenesis [30]. NPY is
also involved in the metabolic syndrome [31], influences proliferation and migration of cells of various
origins [32–34] and possesses important immune-modulatory functions [35].
Six different receptor subtypes were identified and named Y1–5 and y6. Existence of Y3 has
been questioned and a functional receptor subtype y6 has so far only been detected in mice and
rabbits, whereas it is absent in rats and inactive in humans and pigs due to frame-shift mutations [36].
A very elaborate review on NPY receptor signaling was published by Michel et al. in Pharmacological
Reviews in 1998 [37]. All of the Y receptors belong to the pertussis toxin-sensitive Gi or G0 types of the
GPCR family mediating adenylate cyclase (AC) inhibition [38,39]. Pertussis-toxin insensitive receptor
activity of NPY was observed in a small number of studies [40]. Furthermore, NPY receptor activation
was demonstrated to increase intracellular calcium concentration and inositol 1,4,5-triphosphate
(IP3) production [41,42], inhibit voltage-dependent calcium influx [43] and block nicotinic cholinergic
currents [44].
3.2. Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Peptide
VIP and PACAP belong to the glucagon/secretin superfamily of peptide hormones consisting
of nine peptidergic members. PACAP and VIP show high sequence homology and hence share
similar biological activity/effects. PACAP38 is the most ancient member of the family and has
been characterized as a 38-amino-acid peptide from ovine hypothalamic extracts due to its ability
to stimulate cAMP formation in anterior pituitary cells [45]. A shorter variant was isolated
subsequently and termed PACAP27, corresponding to the 27 amino acids from the N-terminal
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region of PACAP38 [46]. PACAP27 shares 68% sequence homology with human VIP identifying
it as a member of the secretin/glucagon family [47]. VIP has first been isolated from porcine small
intestine by Said and Mutt in 1970 and has been characterized as a systemic vasodilator [48]. VIP
is a 28-amino-acid linear peptide derived from a 170 amino acid prepro-peptide also giving rise to
other biologically active peptides [49–51]. PACAP and VIP exert a huge range of biological functions
that will exceed the scope of this review and, therefore, we refer the reader to respective general
reviews in the literature [47,52–54]. The current evidence regarding PACAP/VIP-mediated effects in
the musculoskeletal and immune systems will be elucidated more in detail in the following sections.
VIP and PACAP exert their biological actions via common receptor types. The VIP/PACAP receptors
(VPAC) 1 and 2 have similar affinities for both neuropeptides. PACAP additionally has a 1000-fold
higher affinity for the PACAP receptor 1 (PAC1). VPAC 1 and 2 differ in their tissue distribution and
are expressed differentially during developmental stages. VPAC and PACAP receptors signal via Gs
protein-coupled receptors that activate AC and lead to cAMP accumulation and subsequent protein
kinase A (PKA) activation. By coupling to Gq or Gi, they might also activate phospholipase C (PLC)
which in turn increases Ca2+ levels via IP3 and protein kinase C (PKC) activation via diacylglycerol
(DAG) (reviewed by [55–57]). PAC1 receptor exists in different variations due to alternative splicing
including hip- and hop-cassettes. These variations can either bind to AC and PKC, or to AC alone,
resulting in different signal transduction options [58].
4. Joint Tissues as Target of the Neuroendocrine System
4.1. Synovium
The synovium includes the synovial membrane and the synovial fluid. The synovial membrane is
a thin cellular layer that lines the joint cavity acting as a semipermeable filter to regulate the transfer
of molecules in and out of the joint. It is a major source of the synovial fluid components, including
nutrients, hormones and lubricant factors, such as lubricin and hyaluronic acid. Lubricant factors
contribute to the unique low-friction properties of the articular surface [59]. Various synovial cell
types exert specific functions within the osteoarticular system, e. g., extracellular matrix production,
cytokine secretion, host defense and immunomodulation, to maintain the function of the joint under
physiological conditions [60].
4.1.1. POMC Peptides
In the recent past, POMC peptides were detected in the synovial fluid. A well-known study
reported an increase of β-ED in synovial fluid of RA patients compared to OA patients [61]. In addition
to β-ED, α-MSH was identified in the synovial fluid of patients with rheumatoid arthritis (RA), OA
and juvenile chronic arthritis [62]. The levels of α-MSH were higher in patients with RA than in
those with OA. Moreover, in patients with polyarticular/systemic-onset juvenile chronic arthritis the
concentrations of α-MSH in the synovial fluid were higher than in those with pauciarticular disease.
Recently, it was reported that synovial fluid α-MSH levels showed an independent and negative
correlation with disease severity in patients with posttraumatic ankle osteoarthritis (PTAOA) according
to Mankin scores, and degradation biomarkers CTX-II and AGG-1, as well as inflammation markers
IL-6 and matrix metalloproteinase (MMP)-3 [63]. Recently, our group reported that melanocortin
peptides like α-MSH act as endogenous response modifiers within the synovium. The POMC peptides
previously detected in synovial fluid appear to derive either from the systemic circulation or from
non-fibroblast cell types of the synovial membrane (e.g., macrophages or endothelial cells) since
OA-synovial fibroblasts (OASF) do not synthesize POMC protein [64]. Importantly, various cell types
within this tissue express receptors for POMC-derived peptides. Our group demonstrated that the
MC1R is the only receptor for α-MSH and related peptides in OASFs [64]. We have also shown that
α-MSH elicits biological effects in these cells suggesting an endogenous immunomodulatory role of
melanocortins within the synovium.
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4.1.2. Sympathetic Neuropeptides
Synovial tissue is richly innervated and might serve as a source for various neurotransmitters and
neuropeptides of sensory and sympathetic origin. Nerve fibers positive for the sympathetic marker
enzyme tyrosine hydroxylase (TH) and NPY were detected in human synovium. In comparison to
rheumatoid synovium, the expression in normal synovium was stronger [65]. While initial work
postulated a loss of sympathetic innervation in the synovium of RA patients in relation to normal
and OA synovium [66], Eitner et al. demonstrated the loss of sympathetic nerves in the inflamed
OA synovium in contrast to synovial structures with little inflammation [67]. TH-positive nerves
co-localized with NPY were found in the synovium of Sprague-Dawley rats adjacent to or within blood
vessel walls and also in co-localization with IL-1, whereas VIP-immunoreactivity was seen in varicose
nerve terminals and within vessel walls [68,69]. Synovial NPY-immunoreactivity increased slightly in
Lewis rats with adjuvant-induced arthritis [70]. Equine synovium displays perivascular NPY in the
subsynovium and vessel-associated expression in the fronds [71]. Nerve fibers positive for TH, NPY
and VIP were also found in the normal guinea pig knee joint synovium [72]. NPY-immunoreactivity in
the synovial tissue of various species confirms availability of this peptide in the joint cleft and might
indicate that NPY could contribute to joint-associated diseases. In concordance with that assumption,
synovial fluid concentrations of NPY show strong correlation with inflammation in human and animal
studies in knee and temporomandibular joint (TMJ) arthritis [73–75]. NPY synovial fluid concentrations
might therefore be a good biomarker candidate in OA. A study including 100 OA patients with varying
grades of Watanabe pain scores and radiographic stages demonstrated that increasing synovial fluid
concentrations of NPY positively correlated with pain scores. NPY concentrations in OA patients
were significantly higher compared to controls and NPY synovial fluid concentrations of middle and
advanced stage OA patients were higher compared to early-stage OA patients [76]. Furthermore, NPY
expression increased in the dorsal root ganglion in monoiodacetate-induced OA [77].
VIP-expressing nerves were detected in the cat synovial tissue, normal and arthritic mouse
synovium and periost, as well as in rat synovium [68,78,79]. There have been several studies indicating
that VIP has beneficial effects in synovial cell-derived joint morbidities. In OASF, VIP prevented
ADAMTs (a disintegrin and metalloproteinase with thrombospondin motifs) production, inhibited
aggrecanase activity and degradation of cartilage oligomeric matrix protein and glycosaminoglycan
especially after stimulation with fibronectin fragments (Figure 1A) [80]. VIP levels were reduced
in RA synovial fibroblasts (RASF) compared to OASF cells [81] and VIP stimulation inhibited the
pro-inflammatory phenotype of RASF [82–84]. Synovial fluid concentrations of VIP were elevated in
RA compared to controls and OA [85]. Research on the protective role of VIP on different joint tissues
is predominantly restricted to studies in inflammatory arthritis models. The usefulness of VIP as a
DMOAD deserves more intense investigations because available studies so far emphasize VIP as a
potential inhibitor of joint degradation.
Concomitant to NPY and VIP, PACAP-containing nerve fibers were detected in the synovial
membrane and joint capsule of the TMJ of the rat [86]. PACAP concentrations were reduced compared
to controls in the synovial fluid and cartilage of rats with experimental OA [87]. The synovial tissue
is a potent source for bioactive neuropeptides like NPY, VIP and PACAP that have the ability to
influence joint cell metabolism in degenerative conditions like OA. An indicator for a putative role of
the neuropeptides is the observed fluctuating expression during disease progression.
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Figure 1. Effects of sympathetic neuropeptides on cells of the musculoskeletal system. (A) Vasoactive 
intestinal peptide (VIP) inhibits release of matrix-degrading enzymes a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTs) and aggrecanase from osteoarthritis (OA) 
synovial fibroblasts and prevents degradation of cartilage oligomeric matrix protein (COMP) and 
glycosaminoglycans. (B) Chondrogenic micromass cultures express pituitary adenylate cyclase-
activating peptide (PACAP) receptor 1. Stimulation with PACAP induced collagen type II production 
and inhibited hypertrophic markers collagen type IX and X. In chondrocytes derived from articular 
cartilage, PACAP reduced the interleukin (IL)-1β-induced induction of apoptosis and pro-
inflammatory proteins inducible NO synthase (iNOS) and cyclooxygenase-2 (Cox-2). (C) VIP and 
PACAP inhibit osteoclast-mediated bone resorption and are able to induce IL-6 production in 
osteoblast-like cells. Inhibition of receptor activator of NF-ĸB ligand (Rankl) might support the 
inhibitory effect on osteoclastogenesis. Osteocytes can serve as a local source for neuropeptide Y 
(NPY) in bone, where it might inhibit osteoclastogenesis and enhance osteoblast formation and 
activity. ALP—alkaline phosphatase; red arrow—inhibition; green arrow—activation. 
4.2. Cartilage  
Hyaline cartilage is a highly specialized connective tissue of mesenchymal origin. The only cell 
type within this tissue is the chondrocyte embedded in its self-contrived extracellular matrix (ECM). 
The ECM is composed of a fibrillar compartment of collagen fibrils filled with an extrafibrillar 
compartment, rich in proteoglycans. Unlike other connective tissues, cartilage does not contain blood 
vessels and is not innervated. 
Therefore, oxygen and nutrient supply of chondrocytes is low and depends on diffusion from 
surrounding tissues, e.g., from the perichondrium. This leads to low growth rates and, after injury, 
to limited repair [88,89]. Therefore, and due to the lack of a sufficient number of progenitor cells, 
treatment of chondral defects remains a challenge to medical science. Articular cartilage lesions 
greater than 5 mm2 do not heal spontaneously. Cartilage defects are multifactorial and site-specific. 
Therefore, appropriate therapies need to be individualized and a clear analysis of the underlying 
pathology is needed. Chondral or osteochondral lesions of any type are found in 61% of patients with 
joint pain and are the most prevalent indications for surgical cartilage repair [90]. If left untreated, 
they lead, after a long asymptomatic interval, to full clinical OA. 
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4.2.1. POMC Peptides
Compared to what is known about POMC peptide expression and effects in synovium, much
less is known regarding POMC in cartilage. Our group demonstrated the presence of MC1R, MC2R
and MC5R transcripts in human articular chondrocytes derived from patients with OA [91]. Protein
expression of the MC1R in these cells was confirmed in OA cartilage explants. Here, chondrocytes
located in the middle and deep cartilage layers were immuno-reactive for MC1R while chondrocytes
in the superficial zone were mostly negative. Treatment of these chondrocytes with α-MSH elicited a
cAMP response but not a Ca2+ response. The detection of MC1R in human articular chondrocytes is in
accordance with the observation that also a human chondrosarcoma cell line, likewise expresses
functional MC1R [92]. We and others [91,93] also detected truncated forms of POMC mRNA
(transcripts related to exon 2) in human articular chondrocytes obtained from patients with end-stage
OA. However, POMC transcripts related to exons 2–3 were not detectable [93], suggesting that
articular chondrocytes cannot make functional POMC protein. These findings suggest that expression
of functional POMC transcripts in human chondrocytes is silenced by methylation of the POMC
promoter [12]. In contrast to the unknown role of chondrocytes in the context of POMC peptide
production, it is clearly proven that cartilage is a direct target for POMC-derived peptides. Recently,
Kaneva et al. described the rapid response of articular chondrocytes to mechanical trauma—the
speedy propagation of cartilage inflammation and chondrocyte death, and the ability of melanocortin
peptides α-MSH and (DTRP8)-γ-MSH to temper this response [94]. They report that activation of
both MC1 and MC3 receptor subtypes prevents the progression of trauma-induced chondrocyte
death and the consequential propagation of pro-inflammatory cytokines into non-impacted areas of
cartilage, concomitantly promotes the release of reparative, pro-resolving molecules. These data are in
accordance with our study reporting that when challenged with OA, Mc1re/e mice (MC1R-signaling
deficient mice) develop a more severe OA-pathology [95] (Figure 2). We could further demonstrate
that Mc1re/e mice have a cartilage phenotype prior to OA induction that increases in severity during
OA pathogenesis in an early stage. Unchallenged Mc1re/e mice display smaller articular cartilage
covered areas without OA-related surface erosions, indicating that MC1R-signaling is critical for proper
cartilage matrix integrity and formation. In addition, we suggest that absence of MC1R-signaling
accelerates age-related structural cartilage ECM alterations as demonstrated by loss of collagen II
and increased number of MMP-13 positive chondrocytes. These observations are supported by a
study where adenoviral vectors encoding the human POMC gene were injected intra-articularly after
surgical induction of OA by ACLT (anterior cruciate ligament transection) in rats [96]. POMC gene
transfer decreased the progression and severity of OA and reduced inflammation and angiogenesis
in subsynovial tissues. These effects may be triggered by inhibiting NF-κB activity and by reducing
IL-1β levels like it was demonstrated in HTB-94 chondrosarcoma cells.
4.2.2. Sympathetic Neuropeptides
Although various studies verified the production of neuropeptides and neurohormones in
chondrocytes, there is little evidence for NPY expression in cartilage and chondrocytes. Nunes et al.
observed the expression of NPY in chondrocytes from their transthyretin (TTR) knockout (KO) mice
that show overexpression of peptidylglycine α-amidating monooxygenase (PAM). NPY requires
PAM for amidation to attain full biological activity and as a consequence TTR KO mice show a NPY
overexpression phenotype [97]. The cartilage of these mice did not display an obviously altered
phenotype. In general, research on the influence of NPY on chondrocyte differentiation exhibits
considerable gaps. Furthermore, immunoreactivity against C-flanking peptide of NPY, a sympathetic
marker, was detected in vascular channels of articular cartilage in OA. It is not yet clear, whether these
fibers contain NPY and which role they might play [98].
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Figure 2. Assessment of cartilage degradation after osteoarthritis (OA) induction in Mc1re/re mice. 
(A) Representative images-stained with Safranin O/Fast green-of the medial area from frontal sections 
of right knee joints from non-operated (non-op) and from mice 4 and 8 weeks after osteoarthritis 
induction via destabilization of the medial meniscus (DMM, p.o., post-operation) show disease 
progression over the time. (B,C) 5–6 sections in 60–80 µm intervals of right knees (DMM, B) and left 
knees (Sham, C) show percentages of degraded cartilage area which indicated an OA-progression 
over time in wildtype (WT) (p = 0.0043) and Mc1re/e (p = 0.0095) compared to non-operated controls. 
Mc1re/e mice had more degraded cartilage four weeks (p = 0.0649) and eight weeks (p = 0.0411) after 
OA-induction compared to WT animals. Sham operated knee joints showed similar area of degraded 
cartilage compared to non-operated controls. White bars indicate wild type and grey bars indicate 
mutant group. Bars = 500 µm, §§ p <0.01 4/8 weeks post-surgery vs. non-operated, * p < 0.05 wild type 
vs. Mc1re/e. Adapted from Lorenz et al. [95]. 
Similar to NPY, little is known about PACAP-mediated effects on cartilage. PACAP-
immunoreactivity was detected in cartilage canals innervating blood vessels of the femoral head and 
the patella from pigs [99] indicating that there might be a role for PACAP in this specific tissue. Juhasz 
et al. used mesenchymal cells isolated from ross hybrid chicken embryos of Hamburger–Hamilton 
stages to study the impact of PACAP on chondrogenesis in micromass pellets. Chondrogenic 
micromass cultures expressed mRNA for prepro-PACAP as well as PACAP receptor (also at the 
protein level) and VPAC 1 and 2 mRNA (Figure 1B). Stimulation with PACAP during culture 
enhanced chondrogenic differentiation and PACAP pretreatment diminished oxidative stress [100]. 
In a follow-up study, Juhasz and colleagues showed that mechanical load-induced hypertrophic 
markers were reduced by PACAP application and PACAP receptor gene expression was increased 
(Figure 1B) [101]. The authors did not mention any cartilage phenotype in the PACAP KO mouse 
[102]. Also in 2015, Giunta and colleagues published a study showing that PACAP-expressing 
chondrocytes and PACAP concentration in synovial fluid decreased in a rat OA model. They further 
showed that PACAP reversed IL-1β-induced chondrocyte apoptosis and expression of the pro-
inflammatory proteins inducible NO synthase (iNOS) and Cox-2, in vitro (Figure 1B) [87]. Taken 
together, these few studies indicate a protective role for PACAP in chondrocyte differentiation and 
metabolism. 
Human articular chondrocytes derived from amputation and knee replacement revealed 
enhanced prostaglandin E2 (PGE2) production and caseinase activity, but not cAMP production after 
VIP stimulation [103]. VIP concentration in synovial fluid and articular cartilage detected by ELISA 
and immunohistochemistry correlated negatively with OA showing high expression in controls [104]. 
This loss of VIP in OA-related tissue might prevent initiation of the more pro-inflammatory effects 
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the time. (B,C) 5–6 sections in 60–80 µm ntervals of right kn es (DMM, B) a d left knees (Sham, C)
show percentages of degraded c rtilage ar a which ind cat d an OA-progression over time in wildtype
(WT) (p = 0.0043) and Mc1re/e (p = .0095) compared to non-operated controls. Mc1re/e mice had m re
degrad d cartilage four w eks (p = 0.0649) and eight weeks (p = 0.0411) after OA-induction comp red
to WT animals. Sham operated k ee joints showed similar area of degraded cartilag c mpared to
non-operated controls. White bars indicate wild type nd grey bars indicat mutant group. Bars =
500 µm, §§ p <0.01 4/8 weeks post-surgery vs. non-o erated, * p < 0.05 wild type vs. Mc1re/e. Adapted
from Lor nz et al. [95].
Si ilar to NPY, little is known about PACAP-mediated effects on cartilage. PACAP-immunoreactivity
was detected in cartilage canals innervating blood vessels of the femoral head and the patella from
pigs [99] indicating that there might be a role for PACAP in this specific tissue. Juhasz et al. used
mesenchymal cells isolated from ross hybrid chicken embryos of Hamburger–Hamilton stages to
study the impact of PACAP on chondrogenesis in micromass pellets. Chondrogenic micromass
cultures expressed mRNA for prepro-PACAP as well as PACAP receptor (also at the protein level) and
VPAC 1 and 2 mRNA (Figure 1B). Sti ulation with PACAP during culture enhanced chondrogenic
differentiation and PACAP pretreatment diminished oxidative stress [100]. In a follow-up study,
Juhasz and colleagues showed that mechanical load-induced hypertrophic markers were reduced
by PACAP application and PACAP receptor gene expression was increased (Figure 1B) [101]. The
authors did not mention any cartilage phenotype in the PACAP KO mouse [102]. Also in 2015,
Giunta and colleagues published a study showing that PACAP-expressing chondrocytes and PACAP
concentration in synovial fluid decreased in a rat OA model. They further showed that PACAP reversed
IL-1β-induced chondrocyte apoptosis and expression of the pro-inflammatory proteins inducible NO
synthase (iNOS) and Cox-2, in vitro (Figure 1B) [87]. Taken together, these few studies indicate a
protective role for PACAP in chondrocyte differentiation and metabolism.
Human articular chondrocytes derived from amputation and knee replacement revealed enhanced
prostaglandin E2 (PGE2) production and caseinase activity, but not cAMP production after VIP
stimulation [103]. VIP concentration in synovial fluid and articular cartilage detected by ELISA and
immunohistochemistry correlated negatively with OA showing high expression in controls [104].
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This loss of VIP in OA-related tissue might prevent initiation of the more pro-inflammatory effects
observed by Rahman et al. As mentioned above, Juhasz and colleagues observed the expression
of receptors for VIP (VPAC1 and 2) in their chondrogenic micromass cultures but included no data
regarding VIP-mediated effects during chondrogenesis. So far, VIP effects on chondrocytes seem
controversial with upregulation of PGE2 opposed to the generally anti-inflammatory nature of this
neuropeptide. Especially in collagen-induced arthritis, VIP successfully prevented cartilage and
bone destruction by inhibiting the immense immune activation associated with this disease [105].
In conditions like OA, were immune activation is not the predominant impulse of disease progression,
VIP and, due to the similar nature, also PACAP effects on cartilage degradation and chondrocyte
behavior might be beneficial but require more intense investigations.
4.3. Subchondral Bone
The subchondral bone, tightly connected to the articular cartilage, is an important shock absorber.
The tissue around the interface of bone and cartilage is called the osteochondral zone. It connects the
soft hyaline joint cartilage with the hard spongy bone. This connecting subchondral zone is composed
of the tidemark, a thin structure between the hyaline cartilage and the subjacent calcified cartilage.
Below this structure lies the subchondral bone, which blends into the spongy bone. In healthy joints,
the complicated structure which is termed cartilage adjacent subchondral bone is reported to gradually
relay impacting forces from the soft cartilage to the hard spongy bone [106]. Due to its intimate
connection to the articular cartilage, it plays an important role in cartilage metabolism. Changes in the
peri-articular and subchondral bone contribute to cartilage and joint pathology in OA. These alterations
include the presence of micro-cracks, micro-edema, micro-bleeding within the subchondral region and
the development of subchondral bone cysts [107]. In addition, OA progression is accompanied by the
formation of osteophytes. Osteophyte formation, next to joint space narrowing, subchondral sclerosis,
and subchondral cyst formation, is one of the main radiographic features and diagnostic criteria of
OA [108].
4.3.1. POMC Peptides
In addition to cells of the cartilage, bone-derived cells express multiple MCR subtypes as
demonstrated by independent studies. Dumont et al. reported the presence of MC4R in UMR106.06
rat osteosarcoma cells and in primary rat osteoblasts as well as in the periosteum of newborn mouse
tibial bones. In primary rat osteoblasts, MC2R and MC5R transcripts were also detected (but not
MC1R and MC3R mRNA) [109]. In addition, transcripts of all five MCRs were found in normal human
osteoblasts as well as in MG63 and SAOS-2 osteosarcoma cells, albeit not all receptors were present
in each cell type [110]. There are several reports which describe beneficial effects of POMC-derived
peptides on bone structure and metabolism. ACTH reduces experimental osteonecrosis in rabbits
dramatically [111]. The authors demonstrated that ACTH induces vascular endothelial growth factor
(VEGF) production and supports maturation and survival of osteoblasts in vitro via the ACTH receptor
MC2R. An effect on bone resorption is unlikely as osteoclasts lack MC2R expression. The same
group demonstrated that ACTH regulates bone mass directly, possibly by centrally and locally
produced ACTH [112]. Their work demonstrates that ACTH is capable of significantly increasing
collagen synthesis in osteoblasts. They speculate that ACTH directly binds to ACTH receptors on
bone cells, because direct ACTH stimulation of osteoblasts increased proliferation. Alternatively,
ACTH might be acting synergistically with glucocorticoids (either locally or systemically produced)
to promote osteoblastic differentiation. In addition, ACTH could also be interacting with other
POMC-derived peptides (such as α-MSH or endorphins), which can bind to specific receptors and
modulate osteoblastic activity and function. Contrary to ACTH, α-MSH reduces tibial perimeter and
length [113]. In primary cultures of osteoblasts, α-MSH dose-dependently stimulated cell proliferation
while in bone marrow cultures, α-MSH stimulated osteoclastogenesis. Systemic administration of
α-MSH in mice decreased trabecular bone volume in the proximal tibiae and reduced trabecular
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number. From this, it can be concluded that α-MSH acts directly on bone, increasing bone turnover,
and, when administered systemically, decreasing bone volume. These observations are in line with
our data showing increased bone density and bone mass in MC1R-signaling deficient mice (Mc1re/e)
after surgical OA-induction [95]. We observed alterations in subchondral bone micro-architecture
and osteophyte numbers in Mc1re/e mice after induction of OA. Mutant mice developed clearly
more and larger osteophytes compared to WT. In addition, lack of MC1R signaling led to increased
subchondral bone mass and bone density after OA-induction. In line with an increase in trabecular
thickness and decrease of trabecular separation, our observations indicate a more severe and clearly
faster progression of subchondral OA-related sclerosis in Mc1re/e mice. Notably, we observed similar
effects, however less pronounced, in sham-operated knees at four and eight weeks after surgery with
increased severity in Mc1re/e mice. We were unable to detect OA-related cartilage matrix alterations
in sham-knees of both groups during these time points, indicating that subchondral bone morphology
alterations precede OA-related phenotypical changes in cartilage matrix.
4.3.2. Sympathetic Neuropeptides
Bone cells like osteoblasts, osteoclasts and osteocytes express a wide variety of receptors for a
range of neuropeptides, and substantial efforts have been made over the last decades to decipher
how nervous system-derived molecules can modulate bone metabolism. VIP-positive nerve fibers
were detected in the periosteum and bone of various mammalian species [114–116]. Additionally,
several studies investigated the expression of receptors for VIP and PACAP on osteoblasts and
osteoclasts from different species like human, rat and mouse (reviewed by [117–119]). In calvarial
osteoblasts and the osteoblastic MC3T3-E1 cell line, VIP application elicited a cAMP response and
induced alkaline phosphatase (ALP) gene expression and IL-6 expression [120]. Persson et al. also
observed regulatory properties of VIP in osteoblast-osteoclast co-cultures and in M-CSF (macrophage
colony-stimulating factor)/Rankl (receptor activator of NF-kB ligand)-induced osteoclastogenic
cultures of bone marrow-derived macrophages (BMM). In the first, VIP delayed but enhanced
osteoclastogenesis, whereas in the second setting, VIP inhibited osteoclast formation (Figure 1C) [121].
Juhasz et al. published a review on the role of VIP and PACAP in osteogenesis and chondrogenesis
focusing on signaling pathways [102]. They described a complex auto-regulatory mechanism with VIP
activating the transforming growth factor (TGF)-beta/ bone morphogenetic protein (BMP) signaling
pathway indicating the pro-osteoblastic actions of VIP. The resulting activation of Smads then in turn
regulates VIP expression. In a study from our group, we detected gene expression of VPAC receptor 1
and 2 as well as PACAP receptor 1 in mixed cultures of osteoclasts and BMMs [122]. We could not
confirm that VIP had profound effects on osteoclast numbers, but we measured significantly reduced
cathepsin K activity in cell culture supernatants treated with VIP. Similarly, VIP as well as PACAP38 and
PACAP27, inhibited bone resorption but not number of multinuclear tartrate-resistant acid phosphatase
(TRAP)-positive osteoclast-like cells in enriched cultures derived from rabbit bones [123] (Figure 1C).
From the available literature, it is safe to assume that VIP acts predominantly as an anabolic factor in
bone metabolism by promoting osteogenesis and reducing bone resorption. In disease conditions with
increased bone resorption; VIP, therefore, has the potential to be a valuable treatment option.
Information concerning the actual distribution of PACAP in bone remains incomplete so far, except
for hints that it might be released in the bone marrow and in cartilage canals near the bone [99,124].
Respective receptor expression was demonstrated in osteoblasts and osteoclasts indicating a putative
role for PACAP in bone. In the rat osteosarcoma cell line UMR-106, which is capable of osteogenic
differentiation, PACAP38 (agonist) and PACAP6-38 (antagonist) were able to enhance osteogenic
differentiation by induction of collagen type I, osterix and ALP expression, increased nuclear expression
of Runx2 and elevated deposition of inorganic matrix components into the extracellular matrix [125].
Opposite to these results, stimulation with PACAP and VIP inhibited ALP expression and stimulated
bone catabolic factor IL-6 in the osteoblastic MC3T3 cell line mediated via the VPAC2 receptor [126].
Figure 1C depicts the contradictory findings of VIP-mediated effects on osteoblasts. The conflicting
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data might result from the different origin of cell types used in the respective studies. Probably,
osteosarcoma cell lines are derived from abnormal bone cells and reactions and mechanisms studied in
these cell types may, in part, not reflect physiological reactions. Apart from bone, PACAP expression
was detected in osteoclasts and osteoblasts in the periodontal ligaments after tooth luxation indicating
a role for this neuropeptide in the tooth microenvironment [127].
NPY expression was detected in the developing diaphyseal periosteum, the bone marrow, cartilage
canals of epiphysis and intercondylar eminence and the bone marrow of the epiphysis emphasizing
the importance of NPY during skeletal development [115]. NPY fibers associated to vessels were
found in the periosteum of rat tibia as well as sporadically among bone lining cells and additionally in
Volkmann canals [128,129]. Further evidence for the importance of NPY in bone and especially bone
repair comes from fracture studies showing that NPY expression increased in the fracture callus and
deletion of the Y1 receptor delayed healing [130,131]. NPY can not only be derived from neuronal
sources but can also be produced locally by bone cells, namely osteocytes [132]. NPY promotes
osteogenesis of isolated human mesenchymal stem cells by upregulation of Runx2 and ALP and the
progression of differentiation is correlated with an increased expression of Y1 receptor (Figure 1C) [133]
opposed to the decrease in bone mass mediated via the central Y2 receptor [134]. Studies on NPY and
osteoclasts are less numerous. A study conducted by Khor et al. observed that BMM cultures from mice
lacking y6 receptor expression increased M-CSF/Rankl-induced osteoclastogenesis [135]. Furthermore,
Amano et al. demonstrated that NPY inhibited isoprenaline-induced osteoclast formation in mouse
bone marrow cell cultures (Figure 1C) [136]. Apart from central actions, NPY might be considered as
an anabolic factor in the local bone microenvironment.
5. Effects of the Neuroendocrine System
5.1. Inflammatory and Immune Responses in OA
Clinically, OA is often accompanied by symptoms of joint inflammation, like morning stiffness,
warmth, pain and joint effusions, the latter arising from synovial thickening or synovial fluid
effusion [137]. OA-associated inflammation is characterized as “low-grade” thus differing from
the RA-underlying “high-grade” inflammation [138]. This includes the presence of high levels
of plasma proteins, complement components and cytokines in the synovial fluid and other joint
tissues. Responses of the innate immune system and inflammatory mediators like the complement
system, pattern recognition receptor pathways and mononuclear cell invasion are pivotal to OA
inflammation. In addition to local inflammation in the joint, systemic inflammation might also play
a role in OA pathogenesis. Obesity is known to predispose individuals to OA [139]—possibly not
only by increasing the mechanical load on joints, but also by causing chronic, systemic inflammation
through inflammatory mediators (such as adipokines and other pro-inflammatory cytokines) that are
produced by adipose tissue and released into the bloodstream [140,141]. Weight loss is associated with
a substantial reduction in systemic levels of C-reactive protein and IL-6 in individuals with OA, and
can prevent OA onset or alleviate existing OA symptoms [142,143]. It is possible that the systemic
inflammation associated with chronic inflammatory states, such as obesity or certain chronic diseases,
promotes local inflammation in joints that ultimately results in OA [138]. However, this offers the
opportunity to develop DMOADs for OA that target inflammatory mediators and pathways.
5.1.1. POMC Peptides
A key mediator of cartilage degradation is MMP-13 with clearly elevated levels in joint disorders.
Yoon et al. demonstrated that 200 nM α-MSH inhibits tumor necrosis factor (TNF)-induced MMP-13
expression by decreasing p38 kinase phosphorylation and, thus, preventing subsequent activation of
the NF-kB pathway in HTB-94 chondrosarcoma cells [92]. This is in line with an observation of our
group thatα-MSH reduced secretion of pro-MMP-13 and pro-MMP-2 in addition to suppressing mRNA
levels of IL-1β and TNF in articular OA chondrocytes [91]. Besides, we demonstrated that α-MSH
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stimulation of primary mixed synoviocytes and OASFs reduced TNF, IL-6 and IL-8 secretion [64].
Furthermore, MC1R is the only receptor for α-MSH and related peptides in OASFs. That way the
receptor defines a viable target by which anti-inflammatory therapies could be delivered to potentially
treat inflammatory and degenerative joint diseases.
Transgenic mice overexpressing N-terminal POMC, including α-MSH and γ3-MSH, were
crossed with obese leptin-receptor-deficient mice [144]. Interestingly, the results showed that MSH
overexpression was effective in reducing weight gain and adiposity plus improving glucose tolerance
and insulin sensitivity in lean mice and in genetic mouse obesity models. These results provide support
for the hypothesis that long-term melanocortin activation and treatment could serve as a potential
strategy for anti-obesity therapy subsequently also ameliorating OA pathology and progression.
Intra-articular injection of the POMC gene by using an adenoviral vector carrying the human
POMC gene, inhibited inflammation and angiogenesis in ACLT-induced OA in rats [96]. In addition to
anti-inflammation, other mechanisms may participate in OA suppression by the POMC gene transfer.
Osteochondral angiogenesis causes cartilage loss, osteophyte formation and synovial inflammation,
and facilitates the progression of OA [145]. POMC gene transfer may regulate the expression of
the angiogenic factor VEGF by inhibiting NF-kB activity. Other evidence indicates that POMC gene
delivery inhibited the migration and tube formation capability of endothelial cells [146]. The derived
neuropeptides ACTH and β-EP are also anti-angiogenic [147].
Recently, the group of Perretti performed compound screening in order to identify novel agonists
or positive allosteric modulators (PAM) of the human MC3R [148]. They identified fenoprofen
(a potent cox inhibitor) as a ligand of MCRs (MC3, MC4 and MC5). The novel aspect of these
findings is that a drug with indication for RA and OA might be engaging the melanocortin system,
providing proof-of-concept for MC3R targeting as a treatment for joint diseases. They conclude
that targeting MC3R using PAMs constitutes a viable and biologically effective means to reduce
synovial inflammation.
An interesting approach to target inflammatory arthritic diseases was published by Vessellier et al.
The group generated latent forms of VIP, α-MSH and γ3-MSH by fusion to latency-associated peptide
(LAP from TGF-β) through an MMP cleavage site using recombinant DNA technology [149]. A major
limitation for usage of melanocortins as anti-inflammatory drugs in the clinic is their short half-lives.
The authors demonstrated that these anti-inflammatory peptides can be made latent by insertion into
the LAP shell of TGFβ protecting them from degradation until they reach the site of inflammation
where they can be released by MMPs. In the same line, anti-arthritic effects of a more stable MSH-based
compound, (DTrp8)-γMSH, were associated with protection against alveolar bone loss that is typical
for arthritic mice [150]. Furthermore, in line with data obtained from bone-marrow-derived osteoclasts,
a physiologic control of osteoclast reactivity was observed exerted by MC3R by demonstrating that
Mc3r-null mice develop periodontal disease with accelerated kinetics as they age [151]. Recently,
the group demonstrated that periodontal tissues infected with A. actinomycetemcomitans increased
expression of MC3R, which upon activation reduced alveolar bone loss [152]. Treatment with
(DTrp8)-αMSH reduced the number of TRAP-positive osteoclasts and decreased production of TNFα,
interferon (INF)-γ and IL-17A. In addition, (DTrp8)-αMSH impaired bone resorption by reducing the
number of resorptive pits.
5.1.2. Sympathetic Neuropeptides
VIP and PACAP play important roles in the immune system. Numerous cells of the immune
system are able to produce and secrete VIP, and are modulated by the neuropeptides themselves
through expression of the respective receptors. The presence of VIP-positive nerves in the thymus,
spleen, lymph nodes and mucosal-associated lymphoid tissue further supports the important role of
VIP in immunity [153,154]. PACAP has been detected in cells of lymphoid organs like bone marrow,
spleen, lymph nodes and gut mucosa of the rat by immunostaining, and also in isolated murine
lymphocytes [155,156]. A very comprehensive set of reviews addressing the effects of VIP and PACAP
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on immune cells, comes from Mario Delgado and Doina Ganea. Both researchers emphasize the strong
anti-inflammatory nature of both peptides on cells of the innate and adaptive immune system although
PACAP-related effects require more context-dependent interpretation [157–159]. More recently, it was
reported that VIP prevented acquisition of the pro-inflammatory phenotype in macrophages [160]
and inhibited reactive oxygen species and extracellular trap formation in neutrophils from healthy
volunteers [161]. VPAC1 is the predominant receptor mediating immune regulatory functions although
studies from VPAC2 and PAC1-deficient mice show increased susceptibility to inflammatory disorders.
In humans, reduced levels of VPAC1 on immune cells as well as a reduced response to VIP stimulation
were reported in ankylosing spondylitis, multiple sclerosis, RA and OA [81,162–164]. VIP-based
therapies were especially effective in collagen-induced arthritis [105,165] and its therapeutic potential
has been evaluated in a large number of experimental pathological conditions including inflammatory
bowel disease [166], allergic asthma [167], wound healing [168] and stroke [169]. Scarce availability of
the PACAP receptor 1 might indicate that the role of PACAP is less prominent or more specialized
compared to the structurally related VIP. Similar to VIP, PACAP was able to ameliorate disease outcome
in a murine collagen-induced arthritis model and was very effective in preventing septic shock after
several lipopolysaccharide (LPS) injections in a murine model [159]. Observations from Liu et al.
show that anti-inflammatory M2 macrophages were able to induce PACAP expression in neural
stem/progenitor cells adding to the anti-inflammatory microenvironment [170].
Like VPAC and PACAP receptors, NPY receptors, especially the Y1 subtype have been detected
on almost every type of immune cell so far [171,172]. The aforementioned review highlighted the
role of NPY in numerous inflammatory conditions like inflammatory bowel syndrome, ulcerative
colitis, liver cirrhosis, asthma and atopic dermatitis, as well as autoimmune conditions including
diabetes type I, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. NPY
seems to play an important role in the regulation of phagocytosis and resolution of pathogen invasion
mediated by macrophages and neutrophils [173,174]. Anti- as well as pro-inflammatory effects of
NPY were described in macrophages and dendritic cells indicating the context-dependent role of NPY
in immunity [35,175]. Rather than being a constitutive agent in immune function, NPY might be an
inducible modulator in various immune cells [176,177]. NPY seems to play an important role during
inflammation in fracture healing where it increased in the serum of fractured rats. Additionally, fracture
healing was inhibited by administration of specific receptor antagonists. Immunohistochemistry
revealed accumulation of NPY- and calcitonin gene-related peptide (CGRP)-positive macrophages in
the callus region possibly initiating fracture healing by neuropeptide-induced activation of the ERK
signaling pathway [178]. NPY actions might also include preservation of a stable microenvironment
in the bone marrow niche thereby securing the pool of immune cell progenitors [179,180]. The stem
cell regulatory functions of NPY could highlight the potential of this peptide as a modulatory
supplement in stem-cell-based therapeutic regimens for a range of diseases e.g., osteoporosis (reviewed
by Peng et al. [181]). Regarding OA, studies of the impact of NPY on the immunologic and
degradative mechanisms are lacking and predominantly indicate that NPY participates in pain
mechanisms [76]. These diverse findings suggest highly specific NPY immune actions including
pro- and anti-inflammatory mechanisms that might target very distinctive features of the immune
response. Evaluation of NPY effects might also need to be evaluated in the context of higher hierarchies
of the immune response rather than just the cellular level.
6. Neuroendocrine Peptides: Tools for Treatment of OA?
Current treatments for OA are not regenerative and have little impact on the progressive
degeneration of joint tissues. Clinical interventions are primarily symptomatic with a focus on
pain reduction and control of inflammation with non-steroidal anti-inflammatory drugs and ultimately
through total joint replacement [182,183]. One major reason for this under-representation of
regenerative therapies is, as opposed to isolated focal articular cartilage defects, that regenerative
strategies have to take into consideration the larger sizes of the defects, as well as the underlying
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disease process [184]. Fragile neocartilage constructs produced by implanted or injected mesenchymal
stem cells (MSC) or chondrocytes, together with anti-inflammatory/tissue-protective molecules, may
face rapid degradation when situated in inflamed or diseased joints. Therefore, the underlying
pathology has to be brought effectively under control or any regenerative treatment strategy of OA is
rather short-term and unlikely to be successful long-term. In addition, patients with OA represent a
heterogeneous population in terms of the underlying pathophysiology [185]. This knowledge implies
that joint repair lacks a one-for-all therapy. OA can be divided based on pathophysiological phenotypes
(i.e., bone-, cartilage-, or inflammation-focused) which may affect progression rates. Biomarkers are
needed for the identification of fast-progressors and patient phenotypes so that appropriate patient
populations can be selected for clinical trials and tailored treatments.
6.1. POMC Peptides
The important question arises if POMC-derived peptides and derivatives are promising future
candidates for the treatment of OA. As described above, melanocortin peptides target osteoarticular
key cells in inflammatory diseases—including OA- and modulate pathogenetically relevant key players
including pro-inflammatory cytokines, MMPs, NF-κB or Rankl (Figure 3).
Melanocortins could have several advantages over currently used anti-inflammatory drugs as they
can modulate, but not abrogate, the response of a broad number of cell types. Clinically, administration
of melanocortin peptides to patients with inflammatory (or degenerative) joint disease may be a priori
more advantageous than application of opioids due to the addictive character of the former agents.
The fact that melanocortins not only target virtually all cells of the osteoarticular system but also
those of the immune system [16,186], makes these peptides even more attractive as future therapeutic
candidates for OA. Melanocortin can regulate the inflammatory response without the risk of side-effects
observed with immunosuppressive therapies. Importantly, melanocortin peptides—albeit targeting
immune cells—are rather immunododulators than immunosuppressants. Notably, the melanocortin
analog (DTrp8)-γMSH reduced alveolar bone loss after infection with a Gram-negative coccobacillus
by preventing overexuberant inflammatory responses and bone resorption via osteoclasts [152]. These
data highlight the potential of POMC-derived peptides to target the inflammatory processes and
bone-related processes in OA pathology. Furthermore, MSH peptides might be especially useful
in obesity-induced OA. Overexpression of N-terminal POMC in obese leptin receptor-deficient
mice prevented obesity and preserved normal energy metabolism [144]. Obesity is additionally
associated with a higher individual inflammatory status [187] and thus POMC-derived peptides
might be especially beneficial in obese OA patients due to their ability to modulate metabolic and
anti-inflammatory properties. However, one major challenge encountered with the clinical use
of melanocortin peptides is their rapid degradation in vivo [12]. Oral administration of natural
melanocortin peptides therefore seems to be impossible. Even intravenously administered full-length
α-MSH has a half-life of only a few minutes [188] due to the action of serum proteases [189].
Therefore, development of protease-stable MSH analogues with MCR selectivity, increased potency
but maintained anti-inflammatory efficacy, is a prerequisite to bring melanocortins successfully into
the clinic. In that line, the group of Perretti has undertaken a successful approach to ameliorate
experimental arthritis in mice [149]. They generated a fusion protein consisting of LAP from TGF-β
and γ3-MSH which exerted anti-inflammatory activity and had a half-life of more than 30 h. Finally,
a more promising but challenging strategy in the treatment of inflammatory (or degenerative) joint
diseases may be the exploitation of protease-resistant small peptide derivatives from the C-terminal
domain of α-MSH. MSH tripeptide derivatives such as KdPT do not bind to the MC1R but have potent
anti-inflammatory effects against IL-1β in sebocytes [190].
In this context it will be necessary to clarify which specific MCRs or ORs confer a
chondroprotective function in experimental OA models and in human OA. We have shown that
in an MC1R signaling deficient mouse strain, OA progression was faster and OA scores were more
severe compared to the wildtype (WT) controls indicating a pivotal role of the MC1R in cartilage and
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subchondral bone homeostasis [95]. In addition, the MC3R signaling is implicated in tissue protection
and thus MC1R and MC3R targeting might also qualify as treatments of joint diseases [148].
In conclusion, the use of POMC-derived peptides in OA is most promising when targeting the
ongoing inflammatory processes. The peptides seemingly preserve cartilage and bone structure, but
the exact mechanisms remain uncertain at this point.Int. J. Mol. Sci. 2018, 19, 15 of 26 
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6.2. Sympathetic Neuropeptides
From all the evidence presented above, NPY, VIP and PACAP can surely be considered to
have therapeutic potential in OA. OA is a multi-factorial disease with diffuse and complex etiology.
Neither of the neuropeptides may be adequate to completely cure or prevent OA, but certain aspects
could be targeted and improved such as pain, cartilage degradation, osteophyte formation or bone
alterations. The greatest potential for a beneficial therapeutic effect in OA might be attributed to VIP.
In fact, Jiang et al. reviewed the therapeutic potential of VIP in OA and concluded that VIP offers an
interesting treatment option, but some drawbacks necessitate more intense studies first [191]. In a
study of murine collagen-induced arthritis, VIP was able to abrogate inflammation as well as bone
and cartilage destruction [105], thus identifying VIP as a perfect candidate for application in OA.
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Although OA and RA share certain features like the destruction of cartilage and alterations of bone,
RA remains a disease that is massively driven by autoimmune reactions that might be dissolved by
VIP administration [157]. The immune system participates in OA disease pathology but is not the
main driving force of structural deterioration. Bone destruction in RA is also a result of the massive
expression of the osteoclastogenic factor receptor Rankl [192] which can also be down-regulated by
VIP [193]. Accumulating evidence indicates a role for abnormal bone homeostasis in OA due to a
dysregulated Rankl/osteoprotegerin balance [194] that could be addressed by VIP-based drugs. Lower
VIP synovial fluid concentrations negatively correlated with the Kellgren–Lawrence score and VIP
cartilage content negatively correlated with the histological Mankin score in OA [104]. Thereby, loss
of VIP might contribute to OA pathogenesis and restoration of VIP levels might potentially halt or
abrogate disease progression. Supporting this thesis are several studies demonstrating that VIP has
beneficial effects on synovial cell-derived joint morbidities. Synovitis is a frequent feature of early and
late stage OA that involves infiltration of mononuclear cells, production of pro-inflammatory cytokines
like IL-1β, IL-6 and TNF as well as expression of various matrix-degrading MMPs in the synovial
fluid of OA patients [137,195]. Synovitis and the coherent expression of deleterious molecules might
be prevented by VIP administration [80]. VIP levels of RA synovial fibroblast-like cells (RASF) were
reduced compared to OASF, and VIP stimulation was able to inhibit the highly aggressive destructive
phenotype of RASF [81–84,196]. Reduction of inflammatory molecules and degradative enzymes
would also benefit cartilage preservation. VIP is able to target inflammation and bone metabolism and
its application might thus be suitable for specific OA subtypes. One drawback of peptidergic therapy
lies in the short half-life of the peptides that rapidly reduces bioavailability. Possible solutions include
the packing of peptides into self-assembling micelles thus prolonging their lifespan and delivery of
the micelles directly into the joint cavity. A successful therapeutic approach with VIP packed into
self-assembling micelles was established in a collagen-induced arthritis model and abrogated joint
swelling, cartilage and bone destruction [165]. A major obstacle for VIP as a therapeutic agent in OA is
the possibility that it might promote knee joint allodynia and secondary hyperalgesia in OA joints, an
effect that might also be provoked by administration of PACAP [197,198]. The potent vasodilatory
properties of VIP might also promote unwanted side effects by enhancing immune cell influx into the
joint region.
Similar to VIP, PACAP was described to ameliorate inflammation and cartilage and bone
destruction in a collagen-induced arthritis model probably due to its modulatory role in
immune-related reactions [159,199]. The direct chondroprotective effects of PACAP make it even
more considerable as a therapeutic for OA [87]. More recently, the group of Botz et al. used the
serum-transfer arthritis model in PACAP-deficient and WT mice to elucidate the role of PACAP
in inflammatory arthritis and found some surprising stage-dependent effects. In early arthritis,
PACAP-deficiency ameliorated, and in a later stage it aggravated, arthritis in this model [200]. Hence,
PACAP might not only have beneficial effects, and intention of therapeutic use requires thorough
studies of PACAP availability and specific receptor expression during every stage of OA. More intense
studies should aim to further elucidate the role of the PAC1 receptor. If the VPAC receptors also
transduce signals leading to deleterious effects like afferent nerve sensitization, activation of the PAC
receptor while inhibiting the others might be an option to transmit the beneficial effects of PACAP.
Likewise, NPY synovial fluid concentrations correlated with Watanabe pain score in OA patients
and therefore NPY needs further critical evaluation before being considered as a therapeutic option or
should be preferably considered as a biomarker candidate in OA.
Irrespective of the potential structure-preserving properties of VIP and PACAP, local sensitization
of afferent nerves needs to be prevented before considering them as drugs. In order to prevent
hyperalgesia, it might be necessary to inhibit certain receptors while activating others leading to the
development of combinational therapies. Much more work lies ahead in the future before sympathetic
neuropeptides can be considered in OA therapy.
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7. Conclusions
OA is a heterogeneous disease of all joint tissues and not only of the articular cartilage. Based
on the pathology, OA can be divided into at least three phenotypes which are bone-, cartilage-
or inflammation based that may affect progression and severity of the disease. Besides, future
treatment strategies have to take into account other problems of novel drugs like target-specificity
and side-effects. Neuropeptides such as VIP and NPY and neuroendocrine peptides such as
proopiomelanocortin (POMC)-derived peptides are promising candidates for future treatment options
of OA. POMC-peptides, specifically melanocortins, are partly osteo- and chondro-protective and
all of them show immunomodulatory effects dampening inflammatory processes (Figure 3). Thus,
local application of POMC-derived peptides, i.e., α-MSH, may serve as a potential adjuvant therapy
for delaying the process of posttraumatic OA. However, before the clinical application of these
compounds, problems associated with half-life and stability as well as application strategy (oral versus
intra-articular) have to be solved. Research on the protective role of VIP on different joint tissues is
predominantly restricted to studies in inflammatory arthritis models. Putative effects in OA are of
great interest and deserve more intense investigations because available studies so far emphasize VIP
as a potential inhibitor of joint degradation. From the available literature, it is safe to assume that VIP
acts predominantly as an anabolic factor in bone metabolism by promoting osteogenesis and rather
reducing bone resorption. Therefore, in disease conditions with increased bone resorption VIP has the
potential to be a valuable treatment option.
In conclusion, neuropeptides and neurohormones are a promising source for novel DMOADs but
major obstacles like their quick turnover time and costly production need to be addressed before they
can be considered comparably effective like small molecules including glucosamine derivatives.
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